Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors.

First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. 2018 01 15; 124(2):315-324.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.